Tag Archives: Health Canada

Novo Initiates Zenagamtide CVOT in Obesity; Novo Enters Purchase Agreement for Three Obesity Programs with Kallyope; Health Canada Approves Sandoz Generic Sema

Three cardiometabolic-related news items have been observed: Novo initiated a Ph3 study evaluating zenagamtide for ASCVD (view EUClinicalTrials record); Novo has entered into an asset purchase agreement with Kallyope to acquire three novel obesity drug programs (view LinkedIn post); and Sandoz received Health Canada approval for its generic semaglutide (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

D&D and Pfizer Expand Research Agreement; Dexcom G7 15-Day Health Canada Clearance; Insulet Partners with Calm

Three cardiometabolic-related news items have been observed: D&D Pharmatech extended its oral obesity research agreement with Pfizer (view article), Dexcom received clearance of its G7 15-Day CGM in Canada (view press release), and Insulet partnered with Calm to provide well-being resources for diabetes management (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

New Mounjaro DTC TV Ad; Health Canada Approves Zepbound for OSA; BioAge Doses First Patient in Ph2 QUELL-CV Study

Three cardiometabolic-related news items have been observed: Lilly launched a new Mounjaro DTC TV commercial (view ad), Health Canada approved Zepbound for OSA (view press release), and BioAge Labs dosed the first patient in the Ph2 POC trial of its NLRP3i (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Generic Sema Now in Canada; Roche Posts Petrelintide + Enicepatide Study; Lilly Posts Ph2 Macupatide + Eloralintide Combo Study in Obesity

Three cardiometabolic-related news items have been observed: Apotex launched generic semaglutide in Canada (view press release); Roche posted a Ph2 obesity combination study (view CT.gov record); and Lilly posted a new macupatide + eloralintide combination study (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here